Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.57 |
| ▸ | FAP | Q12884 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 4/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9555045 | 1.00 | DPP4 (0.57) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL30732391 | 1.00 | DPP4 (0.57) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL30732365 | 1.00 | DPP4 (0.57) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL30732326 | 1.00 | DPP4 (0.57) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL16517964 | 1.00 | DPP4 (0.57) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6371844 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29565533 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL30924754 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL825679 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29356868 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622948-B2 | GLP-1/GIP dual agonists | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2026-05-12 | — | — | US | claimed |
| US-20260116944-A1 | NOVEL TRIPLE GLP-1/GIP/GLUCAGON RECEPTOR AGONIST AND A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2026-04-30 | — | — | US | claimed |
| EP-4724471-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | claimed |
| US-20260085094-A1 | STAPLED PEPTIDE AND USE THEREOF | JIANGSU DEYUAN PHARMACEUTICAL CO LTD (CN) | 2026-03-26 | — | — | US | claimed |
| EP-4631973-A1 | NOVEL TRIPLE ACTIVATOR HAVING ACTIVITY ON ALL OF GLP-1, GIP, AND GLUCAGON RECEPTORS, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2025-10-15 | — | — | EP | claimed |
| EP-4603506-A1 | NOVEL GLP-1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CONGENITAL HYPERINSULINEMIA OR HYPOGLYCEMIA, COMPRISING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2025-08-20 | — | — | EP | claimed |
| WO-2025108381-A1 | USE OF GLP-1R/GIPR DOUBLE-TARGET AGONIST IN PREPARING ANIMAL DRUG | 杭州中美华东制药有限公司 | 2025-05-30 | — | — | WO | claimed |
| EP-4556487-A1 | GLP-1/GIP DUAL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | claimed |
| WO-2025052429-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TIRZEPATIDE | NEULAND LABORATORIES LIMITED (IN) | 2025-03-13 | — | — | WO | claimed |
| CN-119522233-A | GLP-1/GIP double agonist and preparation method and application thereof | 杭州中美华东制药有限公司 | 2025-02-25 | — | — | CN | claimed |
| EP-4146681-A2 | ENGINEERED RELAXINS AND METHODS OF USE THEREOF | President and Fellows of Harvard College (US) | 2023-03-15 | — | — | EP | claimed |
| CN-115768460-A | Long-acting GLP-1/GIP dual agonists | 太阳医药工业有限公司 | 2023-03-07 | — | — | CN | claimed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | claimed |
| CN-115651075-A | Synthesis method of Tirzepatide | 杭州信海医药科技有限公司 | 2023-01-31 | — | — | CN | claimed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | claimed |
| CN-115181173-A | Preparation method of Tirzepatide | 深圳市健元医药科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| WO-2022079639-A1 | GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-04-21 | — | — | WO | claimed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | claimed |
| CN-113956348-A | Glucagon and GLP-1 co-agonist compounds | 伊莱利利公司 | 2022-01-21 | — | — | CN | claimed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116944-A1 | NOVEL TRIPLE GLP-1/GIP/GLUCAGON RECEPTOR AGONIST AND A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING THE SAME | GLP1R, GIPR, GCGR | DPP4 66/4885DPP8 63/4885DPP9 43/4885 |
| US-12622948-B2 | GLP-1/GIP dual agonists | GLP1R, GIPR, NPY4R | DPP4 24/4885DPP8 104/4885DPP9 112/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | DPP4 1387/4885DPP8 1451/4885DPP9 1580/4885 |
| US-20260085094-A1 | STAPLED PEPTIDE AND USE THEREOF | VIP, ARGLU1, NGLY1 | DPP4 587/4885DPP8 644/4885DPP9 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.